Molecular selection for ‘smart’ study design in lung cancer

Amanda Psyrri and Barbara Burtness

The ZODIAC trial reported that the addition of vandetanib to docetaxel in second-line treatment of unselected patients with metastatic non-small-cell lung cancer resulted in a statistically significant improvement in progression-free survival compared with docetaxel alone. Identification of biomarkers to assist in molecular selection of patients for targeted therapy is a tool for ‘smart’ clinical trial design.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1